Substance / Medication

Nisoldipine

Overview

Active Ingredient

nisoldipine

RxNorm CUI

7435

Indications

SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Labeler: Covis Pharma US, IncUpdated: 2023-01-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

SULAR is contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

High blood pressure

Prinzmetal angina

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

NCT00311870Phase 4Completed52 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.

Wei Duo, He Wan-Yuan, Lv Qian-Zhou · CNS Neurosci Ther · 2012

PMID: 22533725RCTFull text (PMC)

Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.

Bajcetic Milica, Benndorf Ralf A, Appel Daniel et al. · J Clin Pharmacol · 2007

PMID: 17322141RCT

Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies.

Mundada Veenu P, Patel Mitali H, Mundada Piyush K et al. · Drug Dev Ind Pharm · 2020

PMID: 32031412Observational

Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.

Dudhipala Narendar, Janga Karthik Yadav, Gorre Thirupathi · Artif Cells Nanomed Biotechnol · 2018

PMID: 29688077Observational

Comparative evaluation of proliposomes and self micro-emulsifying drug delivery system for improved oral bioavailability of nisoldipine.

Nekkanti Vijaykumar, Rueda Javier, Wang Zhijun et al. · Int J Pharm · 2016

PMID: 27041124Observational

Tissues distribution of R-(-)- and S-(+)-m-nisoldipine after single enantiomer administration in rats.

Li Min, Wang Qiao, Wang Chunying et al. · Drug Dev Ind Pharm · 2009

PMID: 18821195Observational

Validated LC-MS-MS method for determination of m-nisoldipine polymorphs in rat plasma and its application to pharmacokinetic studies.

Wang Hairong, Zhang Lantong, Wang Qiao et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2006

PMID: 16567136Observational

Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine.

Missan Sergey, Zhabyeyev Pavel, Dyachok Oksana et al. · Br J Pharmacol · 2003

PMID: 14530219ObservationalFull text (PMC)

Comparative study of calcium-channel blockers on cell proliferation, DNA and collagen syntheses, and EGF receptors of cultured gingival fibroblasts derived from human nifedipine, nicardipine and nisoldipine responders.

Matsumoto H, Noji I, Akimoto Y et al. · J Oral Sci · 2001

PMID: 11848193Observational

Comparison of the effects of nifedipine and nisoldipine on coronary vasoconstriction in the Langendorff-perfused rat heart.

Okada T, Izawa N, Nakamura T · J Cardiovasc Pharmacol · 2000

PMID: 10630745Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Nisoldipine (substance)
SNOMED CT: 386861009
UMLS CUI: C0028116
RxNorm CUI: 7435
Labeler: Covis Pharma US, Inc

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.